FY2025 Earnings Forecast for BSX Issued By Leerink Partnrs

Boston Scientific Corporation (NYSE:BSX) – Equities researchers at Leerink Partnrs lifted their FY2025 earnings estimates for Boston Scientific in a research report issued on Wednesday, October 22nd. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will post earnings of $3.04 per share for the year, up from their prior estimate of $2.98. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific’s Q4 2025 earnings at $0.78 EPS, Q1 2026 earnings at $0.79 EPS, Q2 2026 earnings at $0.87 EPS, Q3 2026 earnings at $0.90 EPS, Q4 2026 earnings at $0.96 EPS, FY2026 earnings at $3.52 EPS, FY2027 earnings at $4.03 EPS, FY2028 earnings at $4.56 EPS and FY2029 earnings at $5.12 EPS.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the previous year, the company earned $0.63 earnings per share. The firm’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS.

A number of other research analysts have also recently weighed in on the stock. Robert W. Baird lifted their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research note on Wednesday. Barclays boosted their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Finally, Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $123.77.

Boston Scientific Stock Down 1.3%

BSX opened at $101.08 on Friday. Boston Scientific has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a fifty day moving average of $101.14 and a two-hundred day moving average of $102.08. The stock has a market capitalization of $149.78 billion, a price-to-earnings ratio of 54.06, a PEG ratio of 2.34 and a beta of 0.61.

Hedge Funds Weigh In On Boston Scientific

Large investors have recently made changes to their positions in the stock. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Sound Income Strategies LLC increased its stake in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares during the period. Steph & Co. purchased a new stake in Boston Scientific during the 3rd quarter worth approximately $25,000. 1248 Management LLC purchased a new stake in Boston Scientific during the 1st quarter worth approximately $26,000. Finally, Financial Consulate Inc. purchased a new stake in Boston Scientific during the 3rd quarter worth approximately $25,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. This represents a 58.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 170,214 shares of company stock worth $17,548,337 in the last ninety days. 0.50% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.